Quantcast

For the Treatment of Diabetic Neuropathy, a Drug That Has Disease-Modifying Potential Would Earn Similar Patient Share in the U.S. and Europe

February 22, 2010

WALTHAM, Mass., Feb. 22 /PRNewswire/ – Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of diabetic neuropathy, a drug that has disease-modifying potential would earn 40 percent patient share in the U.S., according to surveyed U.S. neurologists. Similarly, in Europe, such a drug would earn a comparable patient share of 43 percent, according to surveyed European neurologists.

“Interviewed experts told us that there is a great need for disease-modifying agents that can slow or reverse the progression of diabetic neuropathy. They note that currently available drugs focus on alleviating the painful symptoms and that there are no medications to treat the nonpainful symptoms of the disease,” stated Decision Resources Analyst Christine Helliwell, Ph.D. “Therefore, an agent that fulfills such a need has the potential to achieve great commercial success in the U.S. and Europe.”

The new report entitled Diabetic Neuropathy: Significant Opportunity Awaits Agents That Have Disease Modification Potential also finds that CNSBio’s CNSB-001 will earn Decision Resources’ proprietary clinical gold standard in 2013, following its approval for the indication in 2012. CNSB-001 has competitive advantages over the current gold standard, tramadol ER (Ortho-McNeil’s Ultram ER, Labopharm’s Tramadolor/Unitrama/Dolpar/Tridural, generics), in safety and tolerability.

“Although neither CNSB-001 or tramadol ER have disease-modifying capabilities, they earn our clinical gold-standard status because they are efficacious at reducing pain. According to neurologists we surveyed, reduction of pain is the attribute they consider most important in a diabetic neuropathy drug,” added Dr. Helliwell.

About the Report

Diabetic Neuropathy: Significant Opportunity Awaits Agents That Have Disease Modification Potential is a DecisionBase 2010 report. DecisionBase 2010 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or

registered trademarks of their respective holders.


    For more information, contact:

    Decision Resources
    Christopher Comfort
    781-296-2597
    ccomfort@dresources.com

SOURCE Decision Resources


Source: newswire



comments powered by Disqus